|View printer-friendly version|
|September 25, 2003 4:44 p.m.|
|Teva And Aventis Announce That All Relapsing Remitting Multiple Sclerosis Patients in France Will Now Have Access to Copaxone®|
Launch of COPAXONE® in France Expected to Mirror European Success
JERUSALEM, ISRAEL, September 25, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Aventis (NYSE: AVE) announced today that COPAXONE® (glatiramer acetate), used for the treatment of relapsing-remitting multiple sclerosis (RRMS) is now widely available (in both hospitals and private pharmacies) throughout France.